News
Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer
Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital
Sponsored
Discover a new era of healthcare panel engagement: Grounded ...
A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
Deep Dive
Why pharma needs honest patient dialogue
Astellas Pharma US president Percival Barretto-Ko talks with Dr Paul Tunnah about drug pricing, collaboration and improving the patient experience.
Digital
Sponsored
From Pilot to Practice: Insights into AI Adoption, Impact, a...
Read Medidata’s 2nd annual survey, 'The State of AI in Clinical Trials. From Pilot to Practice: Insights into AI Adoption, Impact, and Expectations'.
Market Access
Sponsored
Europe for life sciences and for patients, with BeOne Medici...
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Giancarlo Benelli, SVP & Head of Europe at BeOne Medicines.
R&D
Sponsored
A data-driven guide to small molecule drug discovery and dev...
A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.
Event
Partner Content
10th Dermatology Drug Development Summit
The 10th Dermatology Drug Development Summit returns in 2026 as the leading premier forum dedicated to advancing the discovery, development, and commercialization of innovative therapies for inflam
Event
Partner Content
Better Antifibrotic Decisions Through Cross-Organ Insights
The 10th Antifibrotic Drug Development Summit is the industry's only dedicated forum focused on cross-indication antifibrotic drug development